GOLD 2026 COPD Guidelines: Triple Therapy, Biologics, and Exacerbation Prevention

GOLD 2026: Key Framework Changes

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 report refines the ABE assessment tool introduced in 2023, with updated thresholds for exacerbation risk stratification and expanded pharmacotherapy recommendations. The most significant changes include earlier positioning of triple therapy and the first mention of biologic therapies for select COPD phenotypes.

Triple Therapy: LAMA/LABA/ICS Positioning

The IMPACT and ETHOS trials established that triple therapy (fluticasone furoate/umeclidinium/vilanterol or budesonide/glycopyrrolate/formoterol) reduces exacerbations and all-cause mortality compared to dual bronchodilation in patients with elevated eosinophils (above 100 cells/mcL) and frequent exacerbations. The 2026 guidelines now recommend earlier escalation to triple therapy for Group E patients with blood eosinophils above 100.

Biologics in Eosinophilic COPD

Dupilumab (anti-IL-4/IL-13) demonstrated a 30% reduction in moderate-to-severe exacerbations in the BOREAS and NOTUS trials for patients with blood eosinophils 300 cells/mcL or higher already on triple therapy. This represents the first biologic therapy with robust Phase 3 COPD data and is expected to receive FDA approval for this indication.